151 related articles for article (PubMed ID: 9449240)
1. Different estrogen receptor structural domains are required for estrogen- and tamoxifen-dependent anti-proliferative activity in human mammary epithelial cells expressing an exogenous estrogen receptor.
Zajchowski DA; Webster L; Humm R; White FA; Simmons SJ; Bartholdi M
J Steroid Biochem Mol Biol; 1997 Aug; 62(5-6):373-83. PubMed ID: 9449240
[TBL] [Abstract][Full Text] [Related]
2. The novel estrogen-responsive B-box protein (EBBP) gene is tamoxifen-regulated in cells expressing an estrogen receptor DNA-binding domain mutant.
Liu HL; Golder-Novoselsky E; Seto MH; Webster L; McClary J; Zajchowski DA
Mol Endocrinol; 1998 Nov; 12(11):1733-48. PubMed ID: 9817599
[TBL] [Abstract][Full Text] [Related]
3. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor.
Zajchowski DA; Sager R; Webster L
Cancer Res; 1993 Oct; 53(20):5004-11. PubMed ID: 8402691
[TBL] [Abstract][Full Text] [Related]
4. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
5. Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor.
Garcia M; Derocq D; Platet N; Bonnet S; Brouillet JP; Touitou I; Rochefort H
J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):11-7. PubMed ID: 9328205
[TBL] [Abstract][Full Text] [Related]
6. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
7. Yeast two-hybrid system demonstrates that estrogen receptor dimerization is ligand-dependent in vivo.
Wang H; Peters GA; Zeng X; Tang M; Ip W; Khan SA
J Biol Chem; 1995 Oct; 270(40):23322-9. PubMed ID: 7559488
[TBL] [Abstract][Full Text] [Related]
8. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.
Mahfoudi A; Roulet E; Dauvois S; Parker MG; Wahli W
Proc Natl Acad Sci U S A; 1995 May; 92(10):4206-10. PubMed ID: 7753783
[TBL] [Abstract][Full Text] [Related]
9. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
Lau KM; LaSpina M; Long J; Ho SM
Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
[TBL] [Abstract][Full Text] [Related]
10. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
11. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
Catherino WH; Wolf DM; Jordan VC
Mol Endocrinol; 1995 Aug; 9(8):1053-63. PubMed ID: 7476979
[TBL] [Abstract][Full Text] [Related]
12. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor.
Jiang SY; Jordan VC
J Natl Cancer Inst; 1992 Apr; 84(8):580-91. PubMed ID: 1556769
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.
Coopman P; Garcia M; Brünner N; Derocq D; Clarke R; Rochefort H
Int J Cancer; 1994 Jan; 56(2):295-300. PubMed ID: 8314314
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation.
Duan R; Porter W; Safe S
Endocrinology; 1998 Apr; 139(4):1981-90. PubMed ID: 9528985
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an breast tumor.
England GM; Bilimoria MM; Chen Z; Assikis VJ; Muenzner HD; Jordan VC
Int J Oncol; 1998 May; 12(5):981-6. PubMed ID: 9538117
[TBL] [Abstract][Full Text] [Related]
17. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.
Levenson AS; Catherino WH; Jordan VC
J Steroid Biochem Mol Biol; 1997 Mar; 60(5-6):261-8. PubMed ID: 9219916
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-alpha 1 promoter via a novel sequence.
Elgort MG; Zou A; Marschke KB; Allegretto EA
Mol Endocrinol; 1996 May; 10(5):477-87. PubMed ID: 8732679
[TBL] [Abstract][Full Text] [Related]
19. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.
Herman ME; Katzenellenbogen BS
J Steroid Biochem Mol Biol; 1996 Oct; 59(2):121-34. PubMed ID: 9010327
[TBL] [Abstract][Full Text] [Related]
20. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
